Tasonermin
Beromun · ATC code L03AX11
Also known as: Tasonermina, Tasonermine
- Key facts
- Active substance
- Tasonermin
- Drug class
- Cytovir-3
- ATC code
- L03AX11
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Beromun 1 mg powder for solution for infusion
- Marketing authorisation holder
- Belpharma s.a.
- Information as of
- 2026-10-27
Key facts
Tasonermin is recombinant tumour necrosis factor alpha used with melphalan via isolated limb perfusion to treat soft tissue sarcoma of the limbs.
What it is used for
- Adults with irresectable soft tissue sarcoma of the limbs
- As an adjunct to surgery to prevent or delay amputation, or in the palliative situation
- Only in combination with melphalan via mild hyperthermic isolated limb perfusion (ILP)
Dosing
- Only in specialised centres with experienced teams and an intensive care unit available
- Upper limb: 3 mg total dose by ILP
- Lower limb: 4 mg total dose by ILP
- Melphalan dose based on limb volume, to a maximum of 150 mg
- Administered only if leakage into the systemic circulation is less than 10 %
Contraindications
- Hypersensitivity to the active substance or any excipient
- Significant cardiovascular disease (e.g. heart failure NYHA II–IV, severe angina, recent myocardial infarction, venous thrombosis)
- Severe pulmonary dysfunction, recent or active peptic ulcer, severe ascites
- Significant haematological or renal dysfunction
- Pregnancy; breast-feeding within 7 days of ILP
Important warnings
- Must not be administered systemically
- Continuous monitoring for leakage into the systemic circulation
- Blood pressure, urine output and ECG monitoring for the first 24 to 48 hours after ILP
- Fever and influenza-like symptoms; prophylaxis e.g. with paracetamol before ILP
Side effects
- Most frequent: fever, nausea, vomiting, fatigue, arrhythmia, chills, pain, wound infection, skin reaction
- Common: leukopenia, thrombocytopenia, nerve injury, cardiac failure, thrombosis, shock, hypotension, ARDS
- Uncommon: sepsis, pulmonary oedema
Interactions
- Combinations with cardiotoxic substances (e.g. anthracyclines) should be avoided
- With interferon-gamma, the overall incidence of adverse events is increased without demonstrated added value
Pregnancy and breastfeeding
- Contraindicated in pregnancy
- Breast-feeding is contraindicated within 7 days of ILP
Summary of the official product information, written with AI on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- BeromunBelpharma s.a. · EMEA/H/C/000206
Source: European Medicines Agency (EMA), product information
Brand names in 3 more European countries
- Iceland
- Beromun
- Liechtenstein
- Beromun
- Norway
- Beromun
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Beromun – EPAR, Product Information. 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/beromun-epar-product-information_en.pdf
- Wikidata (CC0): ATC L03AX.
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.